Should You Buy Oscar Health Inc (OSCR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
14.930
1 Day change
0.40%
52 Week Range
23.800
Analysis Updated At
2026/01/26
Oscar Health Inc (OSCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock's technical indicators are bearish, and while there are some positive developments in analyst ratings and financial performance, the lack of strong trading signals, mixed sentiment, and ongoing uncertainties around subsidies and profitability make it prudent to hold off on investing right now.
Technical Analysis
The technical indicators for OSCR are bearish. The MACD histogram is negative and expanding, RSI is neutral at 38.634, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 16.536, with key support at 15.235 and resistance at 17.836.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
9
Buy
3
Positive Catalysts
Analysts have recently upgraded the stock, with price targets increasing to $17 and $18, citing better-than-expected enrollment and potential margin expansion.
Revenue growth in Q3 2025 was strong, up 23.21% YoY, and net income losses improved significantly by 151.76% YoY.
Neutral/Negative Catalysts
The stock's technical indicators are bearish, and the price is declining in pre-market and post-market trading.
Uncertainty around the expiration of enhanced subsidies and its impact on enrollment and profitability.
No significant hedge fund or insider trading activity to indicate strong confidence in the stock.
Financial Performance
In Q3 2025, Oscar Health's revenue increased by 23.21% YoY to $2.99 billion. Net income improved significantly, with losses narrowing by 151.76% YoY to -$137.45 million. EPS also improved by 140.91% YoY to -0.53. However, gross margin remained at 0%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts have shown mixed sentiment. UBS and Barclays upgraded the stock to Neutral and Equal Weight, respectively, with price targets of $17 and $18. Piper Sandler is more optimistic with an Overweight rating and a $25 price target. However, Jefferies and Wells Fargo maintain Underperform ratings, citing risks related to subsidies and medical loss ratios.
Wall Street analysts forecast OSCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 17.04 USD with a low forecast of 11 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OSCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSCR is 17.04 USD with a low forecast of 11 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
2 Sell
Hold
Current: 14.870
Low
11
Averages
17.04
High
25
Current: 14.870
Low
11
Averages
17.04
High
25
UBS
Sell -> Neutral
upgrade
$12 -> $17
AI Analysis
2026-01-09
Reason
UBS
Price Target
$12 -> $17
AI Analysis
2026-01-09
upgrade
Sell -> Neutral
Reason
UBS upgraded Oscar Health to Neutral from Sell with a price target of $17, up from $12. The firm believes that despite the expiration of the enhanced subsidies, Oscar's enrollment in the exchanges are holding up better than feared. UBS says the shares are fairly priced at this level.
Barclays
Andrew Mok
Underweight -> Equal Weight
upgrade
$13 -> $18
2026-01-05
Reason
Barclays
Andrew Mok
Price Target
$13 -> $18
2026-01-05
upgrade
Underweight -> Equal Weight
Reason
Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18, up from $13. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OSCR
